Aurobindo Pharma Ltd’s consolidated net profit increased three fold at ₹417 crore in the third quarter ended December 31, 2013, compared with ₹92 crore in the year-ago period. The total revenue grew 36 per cent at ₹2,140 crore (₹1,570 crore).
The sales in the US had increased by 81 per cent at ₹931 crore and there was growth in other markets as well.
The company’s scrip gained 2.30 per cent to end at ₹493.35 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.